Results 61 to 70 of about 27,891 (313)

Characteristics and outcomes of diabetic patients with an implantable cardioverter defibrillator in a real world setting: results from the Israeli ICD registry [PDF]

, 2016
AIMS: There are limited data regarding the effect of diabetes mellitus (DM) on the risks of both appropriate and inappropriate implantable cardioverter defibrillator (ICD) therapy.
Alexander Tenenbaum, Alon Barsheshet, Boris Strasberg, Enrique Z. Fisman, Gregory Golovchiner, Hillel Steiner, Ilan Goldenberg, Mahmoud Suleiman, Michael Geist, Michael Glikson, Moshe Swissa, null null   +11 more
core   +1 more source

Mechanism‐Informed Machine Learning Enables Discovery of Oncolytic Peptides for Cancer Immunotherapy

Advanced Science, EarlyView.
MISPOP integrates ensemble learning with membrane‐active physicochemical priors to identify Dermaseptin‐S9, a natural oncolytic peptide that disrupts tumor membranes, triggers immunogenic cell death, and shows strong antitumor activity. The study illustrates a mechanism‐informed route from peptide sequence data to cancer immunotherapy leads.
Wen Zhang, Shengxin Lu, Guangyong Zheng, Shensuo Li, Hongyu Chen, Mei Hong, Xiangru Zhou, Ruotian Tang, Ye Wu, Weidong Zhang, Dong Lu, Xin Luan   +11 more
wiley   +1 more source

Differences between therapeutic mechanisms of resmetirom and semaglutide against MASH in western diet-fed MC4R-knockout mice

Scientific Reports
Metabolic dysfunction-associated steatotic liver disease (MASLD) can progress to steatohepatitis (MASH), which is closely associated with obesity and insulin resistance. Resmetirom, and semaglutide, have been shown to have therapeutic effects in clinical
Takumi Sugawara, Kosuke Hitaka, Mitsuharu Matsumoto, Sayuri Nakamura, Ryosuke Kobayashi, Hitoshi Kandori, Yasunori Nio   +6 more
doaj   +1 more source

Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial

Arthritis &Rheumatology, EarlyView.
Objective Overweight or obesity is prevalent in 72% to 82% of individuals with psoriatic arthritis (PsA). We assessed the efficacy and safety of ixekizumab (IXE) concomitantly administered with tirzepatide (TZP) compared with IXE alone in adult participants with active PsA and overweight with at least one weight‐related comorbidity or obesity.
Joseph F. Merola, Philip Mease, Alan Kivitz, Naveed Sattar, Laura C. Coates, Daniel Aletaha, Cynthia E. Kartman, Peter Fischer, Luna Sun, Píndaro Martínez‐Osuna, Andris Kronbergs, Purvi Prajapati, Anabela Cardoso, Mark C. Genovese, Alexis Ogdie   +14 more
wiley   +1 more source

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

Safety considerations of semaglutide in the potential treatment of Alzheimer's disease: A pooled analysis of semaglutide in adults aged ≥ 65 years

Alzheimer’s & Dementia: Translational Research & Clinical Interventions
INTRODUCTION The evoke/evoke+ trials are investigating semaglutide in a population with early Alzheimer's disease (AD). Specific analyses of semaglutide safety data in older adults are limited; therefore, in the current analysis, we aimed to evaluate ...
Marwan Sabbagh, Cristina Boschini, Sharon Cohen, Magnus Fugger, Frank Jessen, Sune Dandanell, Sue D. Pedersen, Luis Rafael Solís Tarazona, Vanita R. Aroda   +8 more
doaj   +1 more source

Effects of Once-Weekly Semaglutide on Cardiovascular Risk Factors and Metabolic Dysfunction-Associated Steatotic Liver Disease in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study Based on Real-World Data

Biomedicines
Once-weekly semaglutide is a widely used glucagon-like peptide-1 receptor agonist (GLP-1RA) used for the treatment of type 2 diabetes (T2D). In clinical trials, semaglutide improved glycemic control and obesity, and reduced major cardiovascular events ...
Hisayuki Katsuyama, Mariko Hakoshima, Emika Kaji, Masaaki Mino, Eiji Kakazu, Sakura Iida, Hiroki Adachi, Tatsuya Kanto, Hidekatsu Yanai   +8 more
doaj   +1 more source

Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review

Frontiers in Endocrinology, 2023
PurposeThis study aimed to perform a network meta-analysis to objectively evaluate the efficacy and safety of 10 Glucagon-like peptide-1 receptor agonists (GLP-1RAs) in combination with metformin that is approved for use worldwide in patients with type 2
Zeyu Xie, Jia Hu, Hangye Gu, Mengting Li, Jisheng Chen   +4 more
doaj   +1 more source

Randomised clinical trial: Semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging [PDF]

, 2021
Background: Glucagon-like peptide-1 receptor agonists may be a treatment option in patients with non-alcoholic fatty liver disease (NAFLD). Aims: To investigate the effects of semaglutide on liver stiffness and liver fat in subjects with NAFLD using non ...
Andersen, Grit, Flint, Anne, Hockings, Paul, Johansson, Lars, Loomba, Rohit, Morsing, Anni, Plum-M\uf6rschel, Leona, Sundby Palle, Mads, Vogl, Thomas   +8 more
core   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source